Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Cerulean reported data from 18 patients with platinum-resistant ovarian cancer in the first stage of an open-label, U.S. Phase II trial showing that 15 mg/m 2 IV CRLX101 plus 10 mg/kg Avastin bevaciz...